Systemic Radiation Therapy is a specialized cancer treatment approach that involves the use of radioactive drugs or substances that are administered into the bloodstream to target cancer cells throughout the entire body. This therapy is designed to deliver radiation therapy internally, reaching cancer cells that may have spread to multiple locations in the body.
Key aspects of systemic radiation therapy include:
Systemic radiation therapy typically involves the use of radioactive drugs or substances. These drugs are specifically designed to target and kill cancer cells while minimizing the impact on healthy tissues.
Depending on the specific treatment and cancer type, the radioactive drugs can be administered orally, such as in the form of radioactive pills, or intravenously (IV), where they are injected into a vein.
Systemic radiation therapy is a form of targeted therapy, as the radioactive drugs specifically seek out and bind to cancer cells or tumor sites. This targeted approach minimizes radiation exposure to healthy tissues.
There are ongoing developments in the field of systemic radiation therapy, including theranostic approaches for various cancer types. Emerging treatments, such as those for metastatic neuroendocrine tumors and prostate cancer, are being explored to improve patient outcomes.
Examples:
Xofigo represents an important treatment option for men with metastatic prostate cancer that has spread to the bones and is causing symptoms. It can help improve the quality of life for these patients by targeting bone metastases and reducing pain and complications associated with bone involvement in prostate cancer. Treatment decisions, including the use of Xofigo, should be made in consultation with a healthcare provider who specializes in cancer care.
Lutathera offers a targeted and promising treatment option for patients with certain types of neuroendocrine tumors. It offers the potential for tumor control and symptom relief, particularly for those with advanced or inoperable disease. Lutathera can be effective in controlling the growth of neuroendocrine tumors and may alleviate symptoms such as abdominal pain, diarrhea, and flushing that are often associated with these tumors.
Pluvicto is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic), and has already been treated with other anticancer treatments. St. Mary's Regional Cancer Center is proud to offer this treatment as it is first and only treatment that targets PSMA+ cancer cells wherever they are in the body.
Patients receiving systemic radiation therapy may need to take precautions to limit radiation exposure to others, particularly to those who are pregnant or have young children. Medical professionals provide guidance on safety measures.
The treatment schedule and duration of systemic radiation therapy may vary depending on the specific treatment and cancer type. Patients typically undergo careful monitoring during and after treatment to assess its effectiveness and manage any side effects.
Systemic Radiation Therapy is an important tool used by St. Mary's Regional Cancer Center in the treatment of certain cancers, especially those that have spread throughout the body. It offers a targeted approach to deliver radiation therapy where it is needed most while sparing healthy tissues, ultimately aiming to improve cancer control and patient outcomes.